The GANSID Inaugurates October 18 as World Inherited Blood Disorders Day
DOVER, DE, UNITED STATES, October 18, 2024 /EINPresswire.com/ Today the Global Action Network for Sickle Cell & Other Inherited Blood Disorders (GANSID), its member organizations, and the extended inherited blood disorders community, celebrate the inaugural World Inherited Blood Disorders Day.
Bill S-288: National Inherited Blood Disorders Day in Canada
Senator Jane Cordy introduced Bill S288- An Act recognizing October 18 of every year as the National Inherited Blood Disorders Awareness Day at the Canadian Senate on September 19, 2024. This move has made Canada a world leader and the first country in the world to recognize inherited blood disorders in this way.
Black History Month: Honoring Black Heroes and History
This month observed in the USA, Canada, UK and Ireland provides us with the opportunity to reflect on the significant impact Black individuals and communities have had in shaping our world, especially in advancing inherited blood disorders including sickle cell disease.
Benefits of Joining Hands for a Common Goal
Many times, individuals and families from around the world with the intention to raise aloft the flag of their health condition/experience often lack the connection, the necessary resources, and the skillsets to sustain their advocacy goals leading to interest waning and advocacy dreams fading into oblivion.
CASGEVY: A Cure for Sickle Cell & Thalassemia Disorders
Casgevy by the Boston-based pharmaceutical company, Vertex is the first medicine to be licensed that uses the innovative genome-editing tool CRISPR, for which its inventors (Emmanuelle Charpentier of the Max Planck Unit for the Science of Pathogens and Jennifer Doudna of the University of California, Berkeley) were awarded the Nobel Prize in Chemistry in 2020.
Many times, individuals and families from around the world with the intention to raise aloft the flag of their health condition/experience often lack the connection, the necessary resources, and the skillsets to sustain their advocacy goals leading to interest waning and advocacy dreams fading into oblivion.
September 26, 2024: The GANSID and its members in Canada serving the sickle cell and thalassemia communities are pleased with the news of CASGEVY receiving marketing authorization for the treatment of these two disorders.
CASGEVY is Canada’s first CRISPR-based gene-editing therapy to receive Health Canada’s marketing authorization.
